Allergy Therapeutics has announced interim top-line results from its pivotal G306 Phase III trial of Grass MATA MPL, a short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate for the treatment of allergic rhinoconjunctivitis due to grass pollen. The trial met its primary endpoint, demonstrating a statistically significant reduction in the Combined Symptom & Medication Score (CSMS) in the active treatment group compared to placebo. The study was stopped for success, and full analysis of the data is expected to be available in mid-December, including treatment effect data and secondary endpoint analysis. The G306 trial was conducted in the US and Europe at 89 sites. Allergy Therapeutics is preparing for a clinical trial application for its G308 paediatric study to meet regulatory requirements.